-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SBe8Zfl+ziurEOnnSqg0Qnlau60Vw1nBD3y2nwa0p0RGNa5+12pKK8I/lzkfz2SQ 0UJKd9D4Rpq6XXHPwOxDqQ== 0000950123-10-009964.txt : 20100208 0000950123-10-009964.hdr.sgml : 20100208 20100208170111 ACCESSION NUMBER: 0000950123-10-009964 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20100208 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20100208 DATE AS OF CHANGE: 20100208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMMERSION CORP CENTRAL INDEX KEY: 0001058811 STANDARD INDUSTRIAL CLASSIFICATION: COMPUTER PERIPHERAL EQUIPMENT, NEC [3577] IRS NUMBER: 943180138 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-27969 FILM NUMBER: 10581530 BUSINESS ADDRESS: STREET 1: 801 FOX LANE CITY: SAN JOSE STATE: CA ZIP: 95131 BUSINESS PHONE: 4084671900 MAIL ADDRESS: STREET 1: 801 FOX LANE CITY: SAN JOSE STATE: CA ZIP: 95131 FORMER COMPANY: FORMER CONFORMED NAME: IMMERSION HUMAN INTERFACE CORP DATE OF NAME CHANGE: 19980602 8-K 1 f54859e8vk.htm FORM 8-K e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
February 8, 2010
Date of Report (Date of earliest event reported)
IMMERSION CORPORATION
(Exact name of Registrant as specified in its charter)
         
Delaware   000-27969   94-3180138
(State or other jurisdiction of   (Commission file number)   (I.R.S. Employer Identification
incorporation)       No.)
           801 Fox Lane, San Jose, CA                                    95131      
(Address of principal executive offices)                      (Zip Code)
(408) 467-1900
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2 below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


 

Item 2.02 Results of Operations and Financial Condition.
     The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 or 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying Exhibit shall not be deemed to be incorporated by reference into any filing with the Securities and Exchange Commission (the “SEC”) made by Immersion Corporation (“Immersion”) whether before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.
     On February 8, 2010, Immersion issued a press release announcing certain of its restated financial results for the years ended December 31, 2006, 2007 and 2008 and the quarter ended March 31, 2009. The press release also includes certain financial results for the quarters ended June 30 and September 30, 2009. The press release is attached to this report as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
     (d) Exhibits.
     
Exhibit No.   Exhibit Title
 
   
99.1
  Press release dated February 8, 2010.

 


 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  Immersion Corporation
 
 
Date: February 8, 2010  By:   /s/ Amie Peters    
    Name:   Amie Peters   
    Title:   Vice President, Legal   
 

 


 

Exhibit List
     
Exhibit No.   Exhibit Title
 
   
99.1
  Press release dated February 8, 2010.

 

EX-99.1 2 f54859exv99w1.htm EX-99.1 exv99w1
Exhibit 99.1
Immersion Investor Contact:
The Blueshirt Group
Alex Wellins, +1-415-217-5861
alex@blueshirtgroup.com
Immersion Concludes Independent Financial Investigation and
Reports Financial Results; Focuses Strategy on Licensing Model
    Completes Independent Financial Investigation and Restatements
 
    Provides Second and Third Quarter 2009 Financial Results
 
    Announces Focus on Licensing Model
 
    Conference Call at 2:30 p.m. PT today, dial 480-629-9714 or 877-941-2321
SAN JOSE, Calif. — February 8, 2010 — Immersion Corporation (NASDAQ: IMMR), the leading developer and licensor of haptic technology, today announced that its Audit Committee has completed its independent financial investigation into certain previous revenue transactions with respect to its medical line of business and that the Company has completed the restatement of its financial results for the fiscal years 2006 — 2008, and the first quarter ended 2009. Immersion also reported financial results for the second and third quarters of fiscal 2009 and announced plans to adopt a pure-play licensing model moving forward.
“We are pleased to have this independent financial investigation completed,” said Victor Viegas, Interim CEO of Immersion. “At a high level, the impact of the restatement since 2006 resulted in the reversal of less than $1 million in revenue that ultimately will not be recognized, an increase in net loss of approximately $2 million, and no change to our reported cash balances. In total, $5.7 million of revenue previously recognized through the first quarter 2009 has either been recognized in a later period, will be deferred to future periods, or will be written off. The Company is actively continuing the process of enhancing its policies and procedures to reduce the chance of recurrence of the issues identified in the independent financial investigation.”
“In addition and after an extensive review of the Company’s business, Immersion’s Board has concluded that applying our licensing model to a highly-targeted number of end-markets and vertical growth sectors offers the most positive outlook for a rapid return to profitability and long-term value for our stockholders. Therefore, while we will continue to pursue the medical segment of the touch market via a licensing approach, our current medical product offerings are no longer core to the Company’s go-forward strategy. We are actively reviewing strategic options for the medical line of business and are engaged in licensing discussions with several parties that are interested in developing and selling medical simulation products.”

 


 

Fiscal 2009 Second Quarter Results
Revenues from Continuing Operations for the second quarter of 2009 were $6.7 million, a decrease of approximately 12% compared to revenues from Continuing Operations of $7.6 million for the second quarter of 2008 and a decrease of approximately 11% compared to revenues from Continuing Operations of $7.5 million for the first quarter of 2009.
Net loss for the second quarter of 2009 was $(8.9) million, or $(0.32) per share, compared to net loss for the second quarter of 2008 of $(3.4) million, or $(.11) per share and net loss of $(6.1) million, or $(0.22) per share, for the first quarter of 2009.
Fiscal 2009 Third Quarter Results
Revenues from Continuing Operations for the third quarter of 2009 were $6.6 million, a decrease of 7% compared to revenues from Continuing Operations of $7.1 million for the third quarter of 2008 and a decrease of approximately 1% compared to revenues from Continuing Operations of $6.7 million for the second quarter of 2009.
Net loss for the third quarter of 2009 was $(9.0) million, or $(0.32) per share, compared to net loss for the third quarter of 2008 of $(33.7) million, or $(1.14) per share and net loss of $(8.9) million, or $(0.32) per share, for the second quarter of 2009.
Business Outlook
“With the largest portfolio of intellectual property related to haptics in the industry, we remain very excited and confident in the opportunity to revolutionize the digital user experience through touch across a broad range of markets including mobile, consumer electronics, entertainment, automotive and medical. While it is premature to provide detailed guidance under our new pure-play licensing strategy, we expect to generate revenue of approximately $25 to $30 million and reach Adjusted EBITDA profitability in fiscal 2010. We plan to maintain a keen focus on operating expenses and expect that the attractive margin profile inherent in our licensing model will allow us to return to profitability. We look forward to reporting our fiscal 2009 fourth quarter and full year results in March and updating investors on our progress regularly,” concluded Mr. Viegas.
Summary of Investigation Findings and Restatement
The investigation began when the Company learned of a potential side agreement dated in the fourth quarter of 2008 between an Immersion Medical sales person and a distributor. After a thorough 8 month investigation into revenue recognition in its medical line of business, that covered more than 15,000 pages of hard copy documents, more than 1.2 million electronic files, and interviews with 17 individuals, the company found several revenue transactions that for different reasons, were not recognized appropriately.

 


 

In total, $5.7 million of revenue identified during the investigation and the preparation of the restatement as prematurely recognized has been restated. The table below reflects the revenue amounts by each year that were originally recorded and impacted by the restatement, and the current state of that revenue in the restated financial statements, either recognized in a later quarter, deferred revenue, or reversed. (For more detailed information, please refer to the Amendment to our Annual Report on 10-K/A for the year ended December 31, 2008 and Amendment to our Quarterly Report on Form 10-Q/A for the quarter ended March 31, 2009, and our Form 10-Qs for the quarters ended June 30, 2009 and September 30, 2009 filed with the Securities and Exchange Commission today.)
                                                         
($ in 000s)   2006   2007   2008   Q1-Q309   Deferred   Reversed   Total
 
Revenue Reported Originally
  $ 125     $ 431     $ 4,671     $ 469     $ 79             $ 5,775  
Revenue after Restatement
    0     $ 642     $ 1,012     $ 2,690     $ 808     $ 623     $ 5,775  
Difference
    ($125 )   $ 211       ( $3,659 )   $ 2,221     $ 729     $ 623          
During the preparation of the restatement, the Company also corrected other accounting errors that were discovered, including:
  Stock-Based Compensation Expense The Company identified a third-party software-based error in its calculated stock-based compensation expense for fiscal 2007, 2008 and the first quarter of 2009.
 
  Interest Income The Company identified an error in the accounting relating to the timing of the recognition of interest income with respect to its patent license with Sony Computer Entertainment that impacted fiscal 2007, 2008 and the first quarter of 2009.
 
  Amortization and Impairment of Intangibles The Company identified instances where amortization for patents, and abandoned patents weren’t treated correctly.
 
  Warrants. The Company had not adopted EITF 07-5 for properly reporting its warrants issued in connection with its convertible debt financing.
Conference Call Information
Immersion will host a conference call with company management on Monday, February 8, 2009 at 2:30 p.m. Pacific time (5:30 p.m. Eastern time) to discuss its prior financial results and go-forward strategy. To participate on the live call, analysts and investors should dial 877-941-2321 at least ten minutes prior to the call. A replay of the call will be available until 11:59 p.m. Pacific time on February 15, 2010 by dialing 800-406-7325 and entering the passcode 4211957#. A live and archived webcast of the conference call will also be available for one year within the investor relations section of Immersion’s corporate Web site at www.immersion.com.

 


 

About Immersion (www.immersion.com)
Haptic (touch) technology is the future of user experience in digital devices. Founded in 1993, Immersion (NASDAQ: IMMR) harnesses human touch to create user experiences that deliver a more compelling sense of the digital world. Using one of Immersion’s adaptable high fidelity haptic systems, partners can achieve a competitive advantage and greater revenue opportunities with products that are more intuitive, satisfying, efficient, and safe. With Immersion technology, world-class companies can deliver improved user experiences in products such as widely popular video games, leading video console gaming systems, advanced automotive driver controls, and award-winning mobile phones. Immersion manufactures its own line of medical simulators that incorporate touch feedback technology. These virtual reality training tools, installed around the world, enable practitioners to improve their practice of sophisticated life-saving surgical procedures prior to operating on patients. With over 800 issued or pending patents in the U.S. and other countries, Immersion is the leading innovator in touch-enabled user experiences that bring the digital universe to life.
Immersion and the Immersion logo are trademarks of Immersion Corporation in the United States and other countries. All other trademarks are the property of their respective owners.
Non-GAAP Measures
This press release includes information on future adjusted EBITDA. This measure is not based on any standardized methodology prescribed by U.S. generally accepted accounting principles (“GAAP”) and is not necessarily comparable to similar measures presented by other companies. Adjusted EBITDA is defined as earnings before interest, taxes, depreciation and amortization after removing the effect of stock-based compensation expense and other non-operating expense. This measure should not be considered in isolation or as a substitute for measures prepared in accordance with GAAP, and because this amount is not determined in accordance with GAAP, it should not be used exclusively in evaluating the Company’s business and operations. The Company believes that this non-GAAP information is useful as an additional means for investors to evaluate the Company’s operating performance, when reviewed in conjunction with the Company’s GAAP financial statements. Management also reviews this information as an additional means for measuring the performance of the Company. The Company compensates for these limitations by realizing that these amounts are not determined in accordance with GAAP and therefore, should not be used exclusively in evaluating its business and operations.
Forward-looking Statements
This press release contains “forward-looking statements” that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause the results of Immersion Corporation and its consolidated subsidiaries to differ materially from those expressed or implied by such forward-looking statements.
All statements, other than the statements of historical fact, are statements that may be deemed forward-looking statements, including, but not limited to, statements regarding the future of the Company’s medical line of business product lines, future financial results and implementation of remedial measures.
Immersion’s actual results might differ materially from those stated or implied by such forward-looking statements due to risks and uncertainties associated with Immersion’s business, which include, but are not limited to, the effects of the current negative macroeconomic climate; delay in or failure to achieve commercial demand for Immersion’s products; a delay in or failure to achieve the acceptance of force feedback as a critical user experience; unexpected difficulties in transitioning to a pure IP licensing model; the commercial success of applications or devices into which Immersion’s technology is licensed; potentially lengthy sales cycles and design processes; adverse outcomes in any intellectual property-related litigation and the costs related thereto; unanticipated difficulties and challenges

 


 

encountered in development efforts; potential restructuring charges; failure to retain key personnel; potential and actual claims and proceedings relating to such matters, including stockholder litigation and action by the SEC or other governmental agencies; and negative tax or other implications for Immersion resulting from the accounting adjustments; and other factors. Many of these risks and uncertainties are beyond the control of Immersion.
For a more detailed discussion of these factors, and other factors that could cause actual results to vary materially, interested parties should review the risk factors listed in Immersion’s most current Form 10-Q, which is on file with the U.S. Securities and Exchange Commission. The forward-looking statements in this press release reflect Immersion’s beliefs and predictions as of the date of this release. Immersion disclaims any obligation to update these forward-looking statements as a result of financial, business, or any other developments occurring after the date of this release.
Immersion, the Immersion logo and TouchSense are trademarks of Immersion Corporation in the United States and other countries. All other trademarks are the property of their respective owners.
(IMMR — C)
###

 


 

IMMERSION CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
                                 
    Three Months Ended     Six Months Ended  
    June 30,     June 30,  
    2009     2008     2009     2008  
Revenues:
                           
Royalty and license
  $ 3,580     $ 3,171     $ 7,361     $ 6,632  
Product sales
    2,772       3,744       6,051       6,324  
Development contracts and other
    330       704       776       1,503  
 
                       
 
                               
Total revenues
    6,682       7,619       14,188       14,459  
 
                       
 
                               
Costs and expenses:
                               
Cost of product sales (exclusive of amortization and impairment of intangibles shown separately below)
    2,312       2,051       3,563       3,735  
Sales and marketing
    4,016       3,846       8,300       7,191  
Research and development
    3,412       2,940       7,341       6,430  
General and administrative
    4,841       5,111       9,226       9,525  
Amortization and impairment of intangibles
    224       202       439       472  
Restructuring costs
    705             1,351        
 
                       
 
                               
Total costs and expenses
    15,510       14,150       30,220       27,353  
 
                       
 
                               
Operating loss
    (8,828 )     (6,531 )     (16,032 )     (12,894 )
 
                               
Change in fair value of warrant liability
    (136 )           344        
Interest and other income
    207       973       510       2,608  
 
                       
 
                               
Loss from continuing operations before provision for income taxes
    (8,757 )     (5,558 )     (15,178 )     (10,286 )
 
                               
Benefit (provision) for income taxes
    (300 )     1,903       (391 )     3,157  
 
                       
 
                               
Loss from continuing operations
    (9,057 )     (3,655 )     (15,569 )     (7,129 )
 
                               
Discontinued operations:
                               
 
                               
Gain on sales of discontinued operations net of provision for income taxes of $0
    20             187        
Gain from discontinued operations, net of provision (benefit) for income taxes of $(48), $133, $102, and $324
    166       210       401       536  
 
                       
 
                               
Net loss
  $ (8,871 )   $ (3,445 )   $ (14,981 )   $ (6,593 )
 
                       
 
                               
Basic and diluted net loss per share
                               
Continuing operations
    (0.33 )     (0.12 )     (0.56 )     (0.23 )
Discontinued operations
    0.01       0.01       0.02       0.01  
 
                       
Total
  $ (0.32 )   $ (0.11 )   $ (0.54 )   $ (0.22 )
 
                       
 
                               
Shares used in calculating basic and diluted net loss per share
    27,968       30,356       27,946       30,417  
 
                       

 


 

IMMERSION CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(Unaudited)
                 
    June 30,     December 31,  
    2009     2008  
ASSETS
Current assets:
               
Cash and cash equivalents
  $ 25,047     $ 64,769  
Short-term investments
    48,962       20,974  
Accounts receivable (net of allowances for doubtful accounts of: June 30, 2009 — $241 and December 31, 2008 — $436)
    4,185       6,114  
Inventories net
    3,672       3,757  
Deferred income taxes
    311       311  
Prepaid expenses and other current assets
    4,012       4,344  
 
           
 
               
Total current assets
    86,189       100,269  
 
               
Property and equipment, net
    3,868       3,827  
 
               
Intangibles and other assets, net
    10,329       9,491  
 
           
 
               
Total assets
  $ 100,386     $ 113,587  
 
           
 
               
LIABILITIES AND STOCKHOLDERS’ EQUITY
 
               
Current liabilities:
               
Accounts payable
  $ 903     $ 2,842  
Accrued compensation
    2,052       2,920  
Other current liabilities
    3,731       3,493  
Deferred revenue and customer advances
    7,833       8,042  
 
           
 
               
Total current liabilities
    14,519       17,297  
 
               
Long-term deferred revenue
    18,131       15,989  
Deferred income tax liabilities
    311       311  
Other long-term liabilities
    217       212  
 
           
Total liabilities
    33,178       33,809  
 
           
 
               
Contingencies
               
 
               
Stockholders’ equity:
               
Common stock and additional paid-in capital — $0.001 par value; 100,000,000 shares authorized; shares issued: June 30, 2009 — 30,779,628 and December 31, 2008 — 30,674,045; shares outstanding: June 30, 2009 — 27,991,759 and December 31, 2008 — 27,887,482
    170,808       167,870  
Warrants
    11       1,731  
Accumulated other comprehensive income
    114       109  
Accumulated deficit
    (85,328 )     (71,543 )
Treasury stock at cost: June 30, 2009 — 2,787,869 shares and December 31, 2008 — 2,786,563 shares
    (18,397 )     (18,389 )
 
           
 
               
Total stockholders’ equity
    67,208       79,778  
 
           
 
               
Total liabilities and stockholders’ equity
  $ 100,386     $ 113,587  
 
           

 


 

IMMERSION CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
                                 
    Three Months Ended     Nine Months Ended  
    September 30,     September 30,  
    2009     2008     2009     2008  
Revenues:
                               
Royalty and license
  $ 2,841     $ 4,761     $ 10,202     $ 11,393  
Product sales
    3,467       1,756       9,518       8,080  
Development contracts and other
    285       538       1,061       2,041  
 
                       
 
                               
Total revenues
    6,593       7,055       20,781       21,514  
 
                       
 
                               
Costs and expenses:
                               
Cost of product sales (exclusive of amortization and impairment of intangibles shown separately below)
    3,293       1,820       6,856       5,555  
Sales and marketing
    2,653       3,919       10,953       11,110  
Research and development
    2,690       3,243       10,031       9,673  
General and administrative
    6,673       4,854       15,899       14,379  
Amortization and impairment of intangibles
    243       201       682       673  
Litigation settlements, conclusions and patent license
          20,750             20,750  
Restructuring costs
    181             1,532        
 
                       
 
                               
Total costs and expenses
    15,733       34,787       45,953       62,140  
 
                       
 
                               
Operating loss
    (9,140 )     (27,732 )     (25,172 )     (40,626 )
 
                               
Change in fair value of warrant liability
    146             490        
Interest and other income
    163       988       681       3,596  
 
                               
Interest and other expense
                (8 )      
 
                       
 
                               
Loss from continuing operations before provision for income taxes
    (8,831 )     (26,744 )     (24,009 )     (37,030 )
 
                               
Provision for income taxes
    (186 )     (7,124 )     (577 )     (3,967 )
 
                       
 
                               
Loss from continuing operations
    (9,017 )     (33,868 )     (24,586 )     (40,997 )
 
                               
Discontinued operations:
                               
 
                               
Gain on sales of discontinued operations net of provision for income taxes of $0
    20             207        
Gain (loss) from discontinued operations, net of provision for income taxes of $209, $252, $307, and $576
    (17 )     165       384       701  
 
                       
 
                               
Net loss
  $ (9,014 )   $ (33,703 )   $ (23,995 )   $ (40,296 )
 
                       
 
                               
Basic and diluted net loss per share
                               
Continuing operations
    (0.32 )     (1.15 )     (0.88 )     (1.36 )
Discontinued operations
    0.00       0.01       0.02       0.02  
 
                       
Total
  $ (0.32 )   $ (1.14 )   $ (0.86 )   $ (1.34 )
 
                       
 
                               
Shares used in calculating basic and diluted net loss per share
    27,994       29,448       27,962       30,092  
 
                       

 


 

IMMERSION CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(Unaudited)
                 
    September 30,     December 31,  
    2009     2008  
ASSETS
Current assets:
               
Cash and cash equivalents
  $ 25,772     $ 64,769  
Short-term investments
    43,968       20,974  
Accounts receivable (net of allowances for doubtful accounts of: September 30, 2009 — $183 and December 31, 2008 — $436
    2,448       6,114  
Inventories, net
    2,291       3,757  
Deferred income taxes
    311       311  
Prepaid expenses and other current assets
    3,333       4,344  
 
           
 
               
Total current assets
    78,123       100,269  
 
               
Property and equipment, net
    3,871       3,827  
 
               
Intangibles and other assets, net
    10,573       9,491  
 
           
 
               
Total assets
  $ 92,567     $ 113,587  
 
           
 
               
LIABILITIES AND STOCKHOLDERS’ EQUITY
 
               
Current liabilities:
               
Accounts payable
  $ 2,350     $ 2,842  
Accrued compensation
    1,304       2,920  
Other current liabilities
    3,458       3,493  
Deferred revenue and customer advances
    6,654       8,042  
 
           
 
               
Total current liabilities
    13,766       17,297  
 
               
Long-term deferred revenue
    18,972       15,989  
Deferred income tax liabilities
    311       311  
Other long-term liabilities
    220       212  
 
           
Total liabilities
    33,269       33,809  
 
           
 
               
Contingencies
               
 
               
Stockholders’ equity:
               
Common stock and additional paid-in capital — $0.001 par value; 100,000,000 shares authorized; shares issued: September 30, 2009 — 30,786,462 and December 31, 2008 — 30,674,045; shares outstanding: September 30, 2009 — 27,998,593 December 31, 2008 — 27,887,482
    171,905       167,870  
Warrants
    11       1,731  
Accumulated other comprehensive income
    121       109  
Accumulated deficit
    (94,342 )     (71,543 )
Treasury stock at cost: September 30, 2009 — 2,787,869 shares and December 31, 2008 — 2,786,563 shares
    (18,397 )     (18,389 )
 
           
 
               
Total stockholders’ equity
    59,298       79,778  
 
           
 
               
Total liabilities and stockholders’ equity
  $ 92,567     $ 113,587  
 
           

 

-----END PRIVACY-ENHANCED MESSAGE-----